Tempus AI, Inc.

Tempus AI, Inc. was founded in 2015 by Eric Lefkofsky following his wife's breast cancer diagnosis. The company builds data and artificial intelligence technology that makes clinical and molecular data actionable for physicians, with the stated aim of improving patient treatment and outcomes. Its work spans artificial intelligence, machine learning, genomic sequencing, bioinformatics and data science, applied chiefly to oncology, precision medicine, pharmaceuticals and drug discovery, and clinical trials.

The company's product line includes Tempus One, an AI-enabled assistant; Lens, a data platform for exploring and accessing clinical and molecular data; and a set of genomic sequencing assays that support personalised treatment decisions. Behind these products sits what the company describes as the world's largest library of clinical and molecular data. Tempus reports connections to 65% of Academic Medical Centers and more than 50% of US oncologists. Its geographic presence is in the United States.

Work at Tempus AI is organised around cross-functional teams in which engineers, data scientists and healthcare experts work side by side. The company describes its culture as valuing collaboration over hierarchy and optimising for impact over facetime, with a diverse staff that includes experts, innovators, cancer survivors, biologists and data scientists. The underlying conviction, stated by the company, is that the right data at the right time can change a patient's path.